Can We Override Clopidogrel Resistance?
2009; Lippincott Williams & Wilkins; Volume: 119; Issue: 21 Linguagem: Espanhol
10.1161/circulationaha.108.857722
ISSN1524-4539
AutoresAna Peña, Jean‐Philippe Collet, Jean‐Sébastien Hulot, Johanne Silvain, Olivier Barthélemy, Farzin Beygui, Christian Funck‐Brentano, Gilles Montalescot,
Tópico(s)Lipoproteins and Cardiovascular Health
ResumoHomeCirculationVol. 119, No. 21Can We Override Clopidogrel Resistance? Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBCan We Override Clopidogrel Resistance? Ana Pena, PhD, Jean-Philippe Collet, MD, PhD, Jean-Sébastien Hulot, MD, PhD, Johanne Silvain, MD, Olivier Barthélémy, MD, Farzin Beygui, MD, PhD, Christian Funck-Brentano, MD, PhD and Gilles Montalescot, MD, PhD Ana PenaAna Pena From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. , Jean-Philippe ColletJean-Philippe Collet From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. , Jean-Sébastien HulotJean-Sébastien Hulot From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. , Johanne SilvainJohanne Silvain From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. , Olivier BarthélémyOlivier Barthélémy From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. , Farzin BeyguiFarzin Beygui From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. , Christian Funck-BrentanoChristian Funck-Brentano From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. and Gilles MontalescotGilles Montalescot From the Institut de Cardiologie, INSERM 937, Université Paris 6 (A.P., J.-P.C., J.S., O.B., F.B., G.M.), and Service de Pharmacologie, Unité de Pharmacogénétique, INSERM 956 (J.-S.H., C.F.-B.), Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Originally published2 Jun 2009https://doi.org/10.1161/CIRCULATIONAHA.108.857722Circulation. 2009;119:2854–2857Clopidogrel, a thienopyridine antiplatelet agent, has been used alone or in association with aspirin to prevent vascular complications in atherothrombotic patients. It is also, in combination with aspirin, the key treatment to prevent stent thrombosis in patients who have undergone percutaneous coronary intervention. It is estimated that >40 million patients worldwide receive clopidogrel. Recent investigations into genetic mechanisms that influence clopidogrel efficacy suggest that a common variant present in ≈30% of whites has the potential to identify patients with a deficient clopidogrel metabolic activation who are consequently at risk of recurrent cardiovascular events, including stent thrombosis.1–3 Stent thrombosis is the most serious complication of coronary stent implantation, often leading to empiric modifications of antiplatelet treatments, although stent thrombosis pathogenesis is complex and the weight of the various factors involved is not known.4 We report 7 recent cases of stent thrombosis with demonstrated platelet resistance to clopidogrel, and we describe a novel clinical approach using pharmacodynamic and genetic information to override clopidogrel resistance.Clinical CasesPatient Selection and CharacteristicsThe clinical characteristics of 7 patients who presented with stent thrombosis on clopidogrel treatment (75 mg maintenance dose [MD]) are presented in the Table. Stent thrombosis was angiographically proven in all patients and occurred on days 1, 3, 5, 6 (2 patients), 11, and 70, with a median time from stent implantation to stent occlusion of 6 days (interquartile range, 4 to 8.5 days). Clinical presentation was ST-elevation myocardial infarction in all cases, and 4 of 7 patients had a history of myocardial infarction. Stent thrombosis occurred in 6 patients with a bare metal stent and 1 patient with a drug-eluting stent. Primary percutaneous coronary intervention revascularization of stent thrombosis was performed with a new bare metal stent in 6 patients; in the remaining patient, a drug-eluting stent was implanted. Table. Baseline Characteristics of the PatientsCharacteristicsOverall (n=7)BMI indicates body mass index; CAD, coronary artery disease; STEMI, ST-elevation myocardial infarction; NSTEMI, non-STEMI; ACE, angiotensin-converting enzyme; and RAA, renin-angiotensin-aldosterone.Mean age, y63 SD15Male gender, %100Mean BMI, kg/m225.9 SD3.6Risk factors, n (%) Familial history of CAD1 (14) Active cigarette smoking3 (43) Dyslipidemia6 (86) Arterial hypertension4 (57) Diabetes mellitus1 (14)Prior ischemic event, n (%) Myocardial infarction4 (57) Ischemic stroke1 (14)Clinical presentation, % STEMI100 NSTEMI0Multiple vessel disease (≥2), n (%)5 (71)Left ventricle ejection fraction (SD), %48 (10)Revascularization, n (%) Bare metal stent6 (86) Drug-eluting stent1 (14)Polyvascular disease, n (%)5 (71)CYP 2C19, n (%) Wild type1 (14) Homozygous*21 (14) Heterozygous*25 (71)Drug therapy during follow-up, % Clopidogrel initiation at first event100 Aspirin100 Statins100 β-Blockers100 ACE inhibitors· · · Calcium blockers· · · Vitamin K antagonist· · · Proton pump inhibitors100 RAA blockers100Laboratory ProceduresPlatelet aggregation studies were performed in all patients in the same laboratory as previously described.5 Aspirin and clopidogrel pharmacodynamic responses were evaluated with light transmission aggregometry (arachidonic acid 1.25 μmol/L and ADP 20 μmol/L; results expressed in percent residual platelet aggregation [RPA]) and with the VerifyNow assay (results expressed in aspirin reaction units with the aspirin cartridge and P2Y12 reaction units and percent inhibition with the P2Y12 cartridge). Aspirin resistance was defined either by an RPA >20% with arachidonic acid or by an aspirin reaction unit ≥550. Clopidogrel resistance was defined by an RPA ≥50% or a P2Y12 reaction unit ≥235 (or percent of inhibition ≤15%). These cutoff values also were used to guide treatment strategies.Genotyping was performed in all patients, with only the 2C19 alleles tested. Genomic DNA was extracted from peripheral blood leukocytes by use of standard procedures (Puregene DNA isolation kit, Merck Eurolab, Hamburg, Germany). CYP2C19*2 (681G>A; rs4244285) was genotyped with a commercially available validated drug metabolism genotyping assay (TaqMan Validated SNP assays C_25986767_70, Applied Biosystems, Foster City, Calif) with the 7900HT sequence Detection System (Applied Biosystems).Response to Clopidogrel and ManagementOnly 1 patient had a poor response to aspirin, and his daily MD was increased from 100 to 200 mg. All 7 patients resistant to a 75-mg MD of clopidogrel were loaded with 900 mg when they were admitted with stent thrombosis and discharged on 150-mg MD. Patients were retested 3 weeks later, and resistance to 150-mg MD of clopidogrel was found again in the 7 patients with both assays (Figure 1). All patients except 1 were found to be carriers of the genetic variant 2C19*2 (5 heterozygous, 1 homozygous), indicating a poor metabolizer profile. To check treatment compliance, a new loading dose of 900 mg clopidogrel also was administered in 4 patients in whom percent of inhibition 50% (Figure 1). Four hours after the load, 2 patients remained fully resistant, whereas the other 2 patients had a mild increase in platelet inhibition (Figure 1). The daily MD of clopidogrel was increased to 225 mg in all patients except 1 who was >80 years of age with a prior history of stroke. Download figureDownload PowerPointFigure 1. Effect of increasing MD of clopidogrel, a reloading dose (RD) of 900 mg clopidogrel, and a 10-mg MD of prasugrel on both RPA using light transmission aggregometry (A) and platelet reaction unit (PRU) and percent inhibition using the VerifyNow P2Y12 point-of-care assay (B). Dashed red line indicates cutoff values for RPA and PRU; solid line, cutoff value for percent inhibition.Three weeks later, resistance to 225-mg MD was found again in 4 of the 6 patients, leading to an increase in the daily MD of clopidogrel to 300 mg in these patients. Three weeks later, 2 patients were still resistant, and 2 had improved platelet inhibition; however, side effects (stomach discomfort and joint pain) did not allow prolongation of such a high MD in these 2 patients. Compassionate use of prasugrel (authorization of temporary use) was sought from the French drug agency (Agence Française de Sécurité Sanitaire pour les Produits de Santé) in 6 of the 7 patients. The last patient died of a new ST-elevation myocardial infarction resulting from recurrent stent thrombosis before the request was sent to the agency. The authorization was obtained for 4 of the 6 patients, and 2 demands were rejected: 1 because of low body weight and 1 for age >75 years. Prasugrel was initiated at 10-mg MD without loading in the 4 resistant patients. Four weeks later, the 4 patients were reevaluated, and all had an optimal response to all tests performed (Figure 1).Figure 2 shows light transmission aggregometry curves in 1 patient, a carrier of 1 allele of the CYP2C19*2 variant who was resistant to all MDs ranging from 75 to 300 mg and to acute reloading with 900 mg, demonstrating that out-of-hospital compliance to treatment was not the issue. In this case, increasing the dose of clopidogrel did not override the effect of the CYP2C19*2, whereas a 10-mg MD of prasugrel did. Download figureDownload PowerPointFigure 2. Effect of different clopidogrel MDs and reloading doses (RDs) and prasugrel on platelet aggregation as measured with light transmission aggregometry using 20 μmol/L ADP as an agonist in a carrier of the 2C19*2 genetic variant (heterozygous) with a prior history of stent thrombosis.CommentsIt has been suggested that in many patients hyporesponsive to a 75-mg MD of clopidogrel, increasing the MD to 150 mg can overcome the poor initial pharmacodynamic response. However, such a strategy appears to work in only 40% of diabetics, a group of patients exposed to frequent vascular ischemic events.6 Stent thrombosis also has been related to inadequate pharmacodynamic response to clopidogrel, and an important clinical question is whether such resistance to clopidogrel is a modifiable factor.7 We report here a series of patients on clopidogrel treatment accumulating clinical resistance (stent thrombosis), biological resistance (high platelet aggregation), and a genetic profile of resistance (2C19*2 genetic variant in 6 of the 7 patients). Our report shows that a strategy of an incremental increase in the clopidogrel MD in such patients is time consuming and minimally effective. Daily MDs of clopidogrel as high as 225 mg were ineffective in the majority of our patients. Increasing the clopidogrel MD up to 300 mg slightly improved platelet inhibition in a dose-effect manner, but only 2 patients became responders to 300 mg daily, and they had side effects precluding continuation of treatment at this dose regimen. All patients who were switched to prasugrel had an impressive and significant improvement in platelet inhibition with all tests used, and there have been no bleeding or side effect concerns over a 3-month period of exposure. Because patients were their own controls for the different MDs of clopidogrel and for prasugrel, the pharmacodynamic information provided here appears to be reliable and important.A large part (80%) of the prodrug clopidogrel is transformed by esterases into inactive metabolites. The conversion of clopidogrel to its active metabolite is a 2-step process involving several cytochrome P450 (CYP) enzymes, and the activity of these CYP enzymes varies considerably between individuals. The loss of function associated with the CYP2C19*2 polymorphism is associated with inactivation of the enzyme and impaired metabolism of clopidogrel, leading to poor response to the drug.8 Prasugrel, the new thienopyridine, is not inactivated by esterases and depends less on CYP2C19 oxidation than clopidogrel. Recent studies have provided compelling new data that underscore the major importance of the CYP2C19*2 polymorphism on clinical outcome of clopidogrel-treated patients, with a rate of stent thrombosis that was greater by a factor 3 to 6 than the rate in noncarriers of the CYP2C19*2 genetic variant.1–3 The rate of carriers is ≈30% in the general white population compared with 85% in our small series, with 5 patients heterozygous (*1/*2) and 1 homozygous (*2/*2). So far, no study has shown the benefit of systematic genotyping to identify CYP2C19*2 carriers and contribute to risk stratification and choice in treatment options for coronary patients. However, our report, focusing on a highly selected group of patients who survived an episode of stent thrombosis and exhibited a poor functional response to clopidogrel, suggests that systematic genotyping combined with platelet functional testing may help physicians choose the optimal antiplatelet strategy. While we wait for randomized studies demonstrating the clinical benefit of tailored antiplatelet therapy on the basis of functional and/or genetic tests, our practical report is the first attempt of such guided strategy in a group of very-high-risk patients exposed to potentially fatal recurrence caused by ineffectiveness of standard therapy. Nowadays, this pharmacogenetic and pharmacodynamic information can be easily obtained and could be useful in many situations involving high-risk vascular patients who can no longer afford clopidogrel failure.We are grateful to E. Villard, G. Anzaha, D. Brugier, and S. Galier for their expert technical assistance.Sources of FundingThis study was sponsored by the Fédération Française de Cardiologie and INSERM.DisclosuresDr Montalescot has received research grants (to the institution) from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Guerbet Medical, Medtronic, Boston Scientific, Cordis, Stago, Centocor, Fondation de France, INSERM, Fédération Française de Cardiologie, and Société Française de Cardiologie; consulting fees from Sanofi-Aventis, Eli Lilly, Bristol-Myers Squibb, The Medicines Co, and Schering Plough; and lectures fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Merck Sharpe & Dohme, Cordis, GlaxoSmithKline, and Schering Plough. Dr Collet has received research grants from Bristol-Myers Squibb, Sanofi -Aventis, Eli Lilly, Guerbet Medical, Medtronic, Boston Scientific Co, Cordis, Stago, Centocor, Fondation de France, INSERM, Federation Francaise de Cardiologie, and Societe Francaise de Cardiologie; consulting fees from Sanofi-Aventis, Eli Lilly, and Bristol-Myers Squibb; and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly. Dr Hulot has received research grants from Fondation de France, INSERM, and consulting fees from Sanofi-Aventis and Eli Lilly. The other authors report no conflicts.FootnotesCorrespondence to Gilles Montalescot, MD, PhD, Bureau 236, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75013, Paris, France. E-mail [email protected] References 1 Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg G, Ferrières J, Danchin N, Becquemont L, for the French Registry of Acute St-Elevation and Non-St-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363–375.CrossrefMedlineGoogle Scholar2 Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354–362.CrossrefMedlineGoogle Scholar3 Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano G, Montalescot G. Cytochrome P450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373: 309–317.CrossrefMedlineGoogle Scholar4 Lüscher T, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007; 115: 1051–1068.LinkGoogle Scholar5 Collet JP, Silvain J, Landivier A, Tanguy Ml, Cayla G, Bellemain A, Vignolles N, Gallier S, Beygui F, Pena A, Montalescot G. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) study. Circulation. 2008; 118: 1225–1233.LinkGoogle Scholar6 Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (Optimus) Study. Circulation. 2007; 115: 708–716.LinkGoogle Scholar7 Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009; 119: 237–242.LinkGoogle Scholar8 Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108: 2244–2247.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Monteyne T, Heireman L, Hemelsoet D, Schaik R and Devreese K (2021) Is monitoring of antiplatelet therapy by light transmission aggregometry dependent on instrument and reagent used?, International Journal of Laboratory Hematology, 10.1111/ijlh.13579, 43:4, (786-794), Online publication date: 1-Aug-2021. Savji N and Berger J (2021) Antiplatelet Therapy ASPC Manual of Preventive Cardiology, 10.1007/978-3-030-56279-3_13, (249-288), . Lee Y, Liao Y, Chang F, Huang H, Tsai J and Chung C (2019) Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population, Journal of the Chinese Medical Association, 10.1097/JCMA.0000000000000101, 82:6, (469-472), Online publication date: 1-Jun-2019. Al Ahmad Y and T. Ali M (2019) Non-ST Elevation Myocardial Infarction: Diagnosis and Management Myocardial Infarction, 10.5772/intechopen.76241 Cattaneo M (2019) P2Y12 Antagonists Platelets, 10.1016/B978-0-12-813456-6.00051-5, (937-956), . Hassen G, Talebi S, Alhadad B, Azhir A, Jennings C, Zavaro D and Kalantari H (2018) Acute stent thrombosis: Should preventative measures start in the emergency department?, The American Journal of Emergency Medicine, 10.1016/j.ajem.2018.05.006, 36:8, (1526.e1-1526.e4), Online publication date: 1-Aug-2018. Regev E, Asher E, Fefer P, Beigel R, Mazin I, Matetzky S and Bugiardini R (2018) Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis, PLOS ONE, 10.1371/journal.pone.0195504, 13:4, (e0195504) Qiu H, Zhang L, Zhu M, Zhang M, Chen J, Feng L, Jia X and Jacob J (2017) Capture of anti-coagulant active ingredients from Moutan Cortex by platelet immobilized chromatography and evaluation of anticoagulant activity in rats, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2017.08.051, 95, (235-244), Online publication date: 1-Nov-2017. Migliori M, Cantaluppi V, Scatena A and Panichi V (2016) Antiplatelet agents in hemodialysis, Journal of Nephrology, 10.1007/s40620-016-0367-5, 30:3, (373-383), Online publication date: 1-Jun-2017. Komosa A, Siller-Matula J, Lesiak M, Michalak M, Kowal J, Mączyński M, Siniawski A, Mularek-Kubzdela T, Wiśniewski S and Grajek S (2016) Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention, Thrombosis Research, 10.1016/j.thromres.2015.12.021, 138, (49-54), Online publication date: 1-Feb-2016. Collet J, Funck-Brentano C, Prats J, Salem J, Hulot J, Guilloux E, Hu M, He K, Silvain J, Gallois V, Brugier D, Anzaha G, Galier S, Nicolas N and Montalescot G (2015) Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study, American Journal of Cardiovascular Drugs, 10.1007/s40256-015-0145-0, 16:1, (43-53), Online publication date: 1-Feb-2016. Roffi M, Patrono C, Collet J, Mueller C, Valgimigli M, Andreotti F, Bax J, Borger M, Brotons C, Chew D, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey R and Windecker S (2015) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, European Heart Journal, 10.1093/eurheartj/ehv320, 37:3, (267-315), Online publication date: 14-Jan-2016. Vélez P and García Á (2015) Platelet proteomics in cardiovascular diseases, Translational Proteomics, 10.1016/j.trprot.2014.09.002, 7, (15-29), Online publication date: 1-Jun-2015. Komosa A, Siller-Matula J, Kowal J, Lesiak M, Siniawski A, Mączyński M, Michalak M, Mularek-Kubzdela T and Grajek S (2014) Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb, Platelets, 10.3109/09537104.2013.877581, 26:1, (43-47), Online publication date: 2-Jan-2015. Windecker S, Kolh P, Alfonso F, Collet J, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Jüni P, Kappetein A, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F, Richter D, Schauerte P, Sousa Uva M, Stefanini G, Taggart D, Torracca L, Valgimigli M, Wijns W and Witkowski A (2015) 2014 ESC/EACTS Guidelines on myocardial revascularization, EuroIntervention, 10.4244/EIJY14M09_01, 10:9, (1024-1094), Online publication date: 1-Jan-2015. Olivier C, Diehl P, Bode C and Moser M (2014) Antithrombozytäre Therapie nach akutem KoronarsyndromAntiplatelet therapy after acute coronary syndrome, Herz, 10.1007/s00059-014-4162-6, 39:7, (808-813), Online publication date: 1-Nov-2014. (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization, European Heart Journal, 10.1093/eurheartj/ehu278, 35:37, (2541-2619), Online publication date: 1-Oct-2014. Horenstein R, Madabushi R, Zineh I, Yerges-Armstrong L, Peer C, Schuck R, Figg W, Shuldiner A and Pacanowski M (2014) Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers, The Journal of Clinical Pharmacology, 10.1002/jcph.293, 54:8, (865-873), Online publication date: 1-Aug-2014. Silvain J, Kerneis M, Collet J and Montalescot G (2014) New Insights for Low Dosing With the New P2Y12 Inhibitors, Circulation Journal, 10.1253/circj.CJ-14-1166, 78:12, (2840-2842), . Liu Y, Yin H and Chen K (2013) Platelet proteomics and its advanced application for research of blood stasis syndrome and activated blood circulation herbs of Chinese medicine, Science China Life Sciences, 10.1007/s11427-013-4551-8, 56:11, (1000-1006), Online publication date: 1-Nov-2013. Mijajlovic M, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V and Bornstein N (2013) Clinical consequences of aspirin and clopidogrel resistance: an overview, Acta Neurologica Scandinavica, 10.1111/ane.12111, 128:4, (213-219), Online publication date: 1-Oct-2013. Collet J and Montalescot G (2013) Personalized antiplatelet therapy: The wrong approach?, Archives of Cardiovascular Diseases, 10.1016/j.acvd.2013.08.001, 106:10, (481-486), Online publication date: 1-Oct-2013. Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D, Klein T, Sabatine M, Johnson J and Shuldiner A (2013) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update, Clinical Pharmacology & Therapeutics, 10.1038/clpt.2013.105, 94:3, (317-323), Online publication date: 1-Sep-2013. Sipeky C, Weber A, Szabo M, Melegh B, Janicsek I, Tarlos G, Szabo I, Sumegi K and Melegh B (2013) High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature, Molecular Biology Reports, 10.1007/s11033-013-2569-4, 40:8, (4727-4735), Online publication date: 1-Aug-2013. Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor S, Barthélémy O, Vignalou J, Beygui F, Brugier D, Martin R, Collet J and Montalescot G (2013) Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2012.09.012, 6:2, (158-165), Online publication date: 1-Feb-2013. Cattaneo M (2013) ADP Receptor Antagonists Platelets, 10.1016/B978-0-12-387837-3.00054-7, (1117-1138), . Becker R, Voora D and Shah S (2013) Hemostasis and Thrombosis Genomic and Personalized Medicine, 10.1016/B978-0-12-382227-7.00052-5, (602-611), . Xie H and Zhang Y (2013) Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs Omics for Personalized Medicine, 10.1007/978-81-322-1184-6_22, (469-506), . Alexopoulos D, Theodoropoulos K, Stavrou E, Xanthopoulou I, Kassimis G, Tsigkas G, Damelou A, Davlouros P, Hahalis G and Athanassiadou A (2012) Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction, Cardiovascular Drugs and Therapy, 10.1007/s10557-012-6407-z, 26:5, (393-400), Online publication date: 1-Oct-2012. Hulot J, Collet J and Montalescot G (2012) Résistance au clopidogrel, tests génétiques et tests fonctionnels, Archives of Cardiovascular Diseases Supplements, 10.1016/S1878-6480(12)70833-9, 4:3, (209-216), Online publication date: 1-Sep-2012. Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen C and Strobl F (2012) Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial, European Radiology, 10.1007/s00330-012-2441-2, 22:9, (1998-2006), Online publication date: 1-Sep-2012. Voora D and Ginsburg G (2012) Clinical Application of Cardiovascular Pharmacogenetics, Journal of the American College of Cardiology, 10.1016/j.jacc.2012.01.067, 60:1, (9-20), Online publication date: 1-Jul-2012. Welsh R, Rao S, Zeymer U, Thompson V, Huber K, Kochman J, McClure M, Gretler D, Bhatt D, Gibson C, Angiolillo D, Gurbel P, Berdan L, Paynter G, Leonardi S, Madan M, French W and Harrington R (2012) A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention, Circulation: Cardiovascular Interventions, 5:3, (336-346), Online publication date: 1-Jun-2012. Silvain J, Cayla G, Hulot J, Finzi J, Kerneis M, O'Connor S, Bellemain-Appaix A, Barthelemy O, Beygui F, Collet J and Montalescot G (2011) High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study, European Heart Journal, 10.1093/eurheartj/ehr407, 33:10, (1241-1249), Online publication date: 2-May-2012. Roberts J, Wells G, Le May M, Labinaz M, Glover C, Froeschl M, Dick A, Marquis J, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob M and So D (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial, The Lancet, 10.1016/S0140-6736(12)60161-5, 379:9827, (1705-1711), Online publication date: 1-May-2012. Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Kónyi A, Pintér T, Horváth I and Komócsi A (2011) Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity, European Journal of Clinical Investigation, 10.1111/j.1365-2362.2011.02594.x, 42:4, (384-392), Online publication date: 1-Apr-2012. Aguiar C (2012) Platelet inhibition in acute coronary syndromes: A complex intervention that needs optimization, Revista Portuguesa de Cardiologia (English Edition), 10.1016/j.repce.2012.02.005, 31:4, (275-277), Online publication date: 1-Apr-2012. Aguiar C (2012) Inibição plaquetária nas síndromes coronárias agudas: uma intervenção complexa que deve ser otimizada, Revista Portuguesa de Cardiologia, 10.1016/j.repc.2012.02.011, 31:4, (275-277), Online publication date: 1-Apr-2012. Alexopoulos D (2011) Prasugrel resistance: Fact or fiction, Platelets, 10.3109/09537
Referência(s)